title: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
abstract: In order to document further the onset of action of alfuzosin, a selective alpha-1 blocker, 93 symptomatic patients with benign prostatic hypertrophy were randomly allocated to a single oral dose of either alfuzosin 1.25 mg or 2.5 mg, or placebo, after a 1-week placebo lead-in period. The effects on flow rates were assessed 1 h 30 min after administration. Peak and mean flow rates were significantly increased in the alfuzosin groups, as compared with placebo, in a dose-dependent manner. After a single intake of placebo, the mean values of these 2 parameters showed little change. The effect on the cardiovascular system (heart rate and blood pressure) was mild. This study indicates that the action of alfuzosin is already present 1 h 30 min after administration.
authors.affiliation: Hôpital St Louis and Synthélabo Recherche, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Teillac
authors.forename: M C
authors.initials: MC
authors.lastname: Delauche-Cavallier
authors.forename: P
authors.initials: P
authors.lastname: Attali
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000503:physiopathology*; D011799:Quinazolines / Q000627:therapeutic use*; D013997:Time Factors; D014554:Urination / Q000187:drug effects*; D014555:Urination Disorders / Q000188:drug therapy / Q000503:physiopathology; D014563:Urodynamics
chemical_list: D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin